Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs State Street SPDR S&P Biotech ETF — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $2.16, while State Street SPDR S&P Biotech ETF trades at $154.37. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MSTU | XBI | |
|---|---|---|
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $92.70 | $164.28 |
52-Week Low | $1.46 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTU is trading at $1.98, up 6.45% today, but faces significant headwinds with a bearish technical outlook and concerning fundamental metrics. The leveraged ETF structure has resulted in substantial losses, with reports indicating a 98% decline from November 2024 levels. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while key financial ratios remain unavailable for analysis.
The outlook remains challenging due to the ETF's leveraged structure and volatility decay. Investment opportunities are limited given the historical performance, while risks include continued erosion of value from daily rebalancing and dependence on MicroStrategy's underlying performance. The fund's viability remains in question based on recent performance trends.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
